In Klinefelter Syndrome Patients, What are the Common Behavioral Problems?
Discussion Klinefelter syndrome (KS) is a common genetic abnormaly with a prevalence of 1 in ~650 male births. It was first described in 1942 by Dr. Harry Klinefelter. It is associated with at least one extra X chromosome with the most common karyotype (~80% of patients) being 47 XXY. Other karyotypes are seen along with mosaicism. It is believed that although it is very prevalent, only about 25-33% of people with KS are identified. About 10% are identified before puberty with the rest usually identified because of hypogonadism and tall stature especially in teenage years or due to infertility in adulthood. KS is diagnosed by karyotype. The phenotype varies but most commonly is associated with hypogonadotropic hypogonadism, infertility, gynecomastia and tall stature. The tall stature is remarkable for a lower segment> upper segment body habitus which can be noted after age 5 years. It is felt that the SHOX gene located on the X chromosome may play a part in this growth pattern. KS patients have underdeveloped genitalia with small phallus and small testes (or cryptochidism). The testes have changes from fetal life but the testes start to enlarge at the time of puberty and then rapidly undergo fibrosis particularly of the Sertoli cells. Patients have elevated follicle-stimulating hormone and luteinizing hormone, but decreased testosterone. Decreased androgen can lead to decreased body hair or muscle strength and treatment with testosterone is usually given in adolescence if...
This study aimed to assess the relative safety and short-term efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (c-TACE) for treating peculiar anatomical sites of gastric cancer liver metastasis. MATERIAL AND METHODS Of the 68 patients with gastric cancer liver metastases confirmed by imaging and pathology, 35 were treated with DEB-TACE and 33 with c-TACE. The DEB-TACE group comprised 26 males and 9 females aged 28-75 years (56.8±6.3), and the c-TACE group included 19 males and 14 females aged 33-77 (60.2±9.4) years. Liver functions of th...
CONCLUSIONS The network pharmacology analysis reveals the molecular biological mechanism of Artemisia annua anti-NSCLC via multiple active components, multi-channels, and multi-targets. This suggests that Artemisia annua might be developed as a promising anti-NSCLC drug. PMID: 32474568 [PubMed - in process]
New J. Chem., 2020, Accepted Manuscript DOI: 10.1039/D0NJ01814G, PaperGurpreet Kaur, Monika Chaudhary, Kailash C Jena, Narinder Singh Abstract Environmental contamination due to increase in drug level is touching its alarming stage. There is an array of drugs such as antibiotics, antidepressants, analgesics, cancer chemotherapy drugs etc which... The content of this RSS Feed (c) The Royal Society of Chemistry
Analyst, 2020, Advance Article DOI: 10.1039/D0AN00627K, PaperJun Liu, Cheng Cao We propose a novel GSH-generating prodrug to be used with a sulfonamide-induced “integrative” platform for selective cancer therapy. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Publication date: Available online 31 May 2020Source: Environmental Toxicology and PharmacologyAuthor(s): Badmus O. Olufunto, Njan Anoka, Ologe M. Olufunmilayo, Olatunji A. Lawrence
The fellows focused on clarity and concision as they discussed topics ranging from oxidative stress to autism. (read more)
Research by NIEHS scientists could open the door to improved infertility treatments. (read more)
Providers involved in the care of children, adolescents, and adults with mental health issues are rightly focused on stabilizing those individuals. However, they should not forget the families and communities; they, too, are grieving with the toll of t...
We compared the efficacy and safety of transcranial direct current stimulation (tDCS) vs. Sertraline in the treatment of Major Depressive Disorder (MDD) in South Korean participants. This was a multi-center, double blind, active controlled study with non-i...
Hi everyone! I’m looking for advice on which schools to apply to in this cycle. I qualify as Disadvantaged on AMCAS and have FAP so I am able to apply to 20 schools. I’ve left off the Philly schools for personal reasons but am open to any other suggestions for my school list. cGPA: 3.7, sGPA: 3.6 For additional context, I had a really rough first 3 semesters of undergrad which included loss of income for my family, a parent’s cancer diagnosis, and 2 hospitalizations for... WAMC/School List: 3.7 cGPA/3.6 sGPA/515 MCAT
More News: Academia | ADHD | Anxiety | Autism | Autoimmune Disease | Boys | Breast Cancer | Cancer | Cancer & Oncology | Cancer in Adolescents | Children | Concerta | Databases & Libraries | Depression | Diabetes | Diabetes Mellitus | Disability | Eating Disorders & Weight Management | Education | Endocrinology | Genetics | Gynecomastia | Health | Hormones | Hospital Management | Hospitals | Hyperactivity | Infertility | Klinefelter's Syndrome | Learning | Low Testosterone | Lupus | Metabolic Syndrome | Methylphenidate | Neurology | Obesity | Orthopaedics | Osteoporosis | Pediatrics | Pregnancy | Pregnancy and Breast Cancer | Psychiatry | Psychology | Reproduction Medicine | Ritalin | Schizophrenia | Speech Therapy | Speech-Language Pathology | Turner Syndrome | Universities & Medical Training | Varicose Veins